Year: 2025
Type: article
Abstract: The author, a physician who has younger‐onset Alzheimer's disease (AD), recounts his recent lunch with a former coworker who has had a stroke. The author makes the point that because we now have an effective treatment for AD, and phosphorylated tau217 is a sensitive and specific screening test for AD, we should advocate for its usage in Medicare Wellness Visits, given that the adage “Time Is Brain” is just as apropos for AD as it has been in stroke care. However, at this time, Medicare is not paying for the lab test.
DOI: 10.1002/trc2.70126
Author: Brent W. Beasley
Institution: University of Oklahoma - Tulsa
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,540
OpenAlex ID: W4411529518